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Abstract
Purpose Treatments for patients with metastatic castration-resistant prostate cancer (mCRPC) have expanded rapidly. They 
include the chemotherapies docetaxel and cabazitaxel, hormonal drugs abiraterone and enzalutamide, and best supportive 
care (BSC). Cabazitaxel has proven to be the last life-prolonging option, associated with a significant risk of serious adverse 
events. Given the lack of real-world evidence, we aimed to compare healthcare resource utilization (HRU) and costs in 
patients with mCRPC treated with cabazitaxel, docetaxel, abiraterone, enzalutamide, and BSC.
Methods We used 2014–2017 claims data from a large German statutory health insurance fund, the Techniker Krankenkasse, 
to identify patients with mCRPC. Patient allocation to individual therapy regimens was based on clinical knowledge and 
included therapy cycles, duration of therapy, and continuous treatment. The study period lasted from the first claim until 
death, the end of data availability, a drug switch, or discontinuation of therapy, whichever came first. Multivariate regression 
models were used to compare monthly all-cause and mCRPC-related HRU and costs across cohorts by adjusting for baseline 
covariates (including age and comorbidities).
Results The 3944 identified patients with mCRPC initiated treatment with cabazitaxel (n = 240), docetaxel (n = 539), 
abiraterone (n = 486), enzalutamide (n = 351), or BSC (n = 2328). In most domains, HRU was highest in the cabazitaxel 
cohort and lowest in the BSC group. Accordingly, the highest all-cause and mCRPC-related costs per month, respectively, 
were observed in patients receiving cabazitaxel (€7631/€6343), followed by abiraterone (€5226/€4579), enzalutamide 
(€5079/€4416), docetaxel (€2392/€1580), and BSC (€959/€438). Cost variations were mostly attributable to drugs, inpa-
tient treatment, and sick leave payments.
Conclusion mCRPC treatment imposes a high economic burden on statutory health insurance. Cabazitaxel is associated 
with substantially higher expenses, resulting from higher drug costs and a greater need for inpatient treatment. As mCRPC 
continues to be incurable, decision makers and clinician leaders should carefully evaluate public access to innovative agents 
and optimal treatment strategies.
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Key Points for Decision Makers 
Patients with metastatic castration-resistant prostate 
cancer (mCRPC) treated with cabazitaxel have more 
hospital admissions and substantially higher monthly 
treatment costs than patients treated with docetaxel, abi-
raterone, enzalutamide, and best supportive care.
In choosing a treatment, the clinical management of 
mCRPC should carefully weigh expected survival 
against potential adverse events and the financial burden 
resulting from healthcare resource utilization.
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1 Introduction
Castration-resistant prostate cancer (CRPC) is an advanced 
form of cancer where the disease progresses despite medi-
cal or surgical treatments to lower androgens. Approxi-
mately 10–20% of patients with prostate cancer (PC) 
become hormone refractory within 5 years after diagnosis. 
At CRPC diagnosis, over 84% of patients have metastases. 
Of the remaining patients, one-third could expect metasta-
sis diagnoses within 2 years [1, 2]. Although, in 2010, the 
median overall survival after metastatic CRPC (mCRPC) 
diagnosis was reported to be 9–13 months [1], new treat-
ments have increased median survival to approximately 
16–35 months, depending on the tumor burden [3]. In 
Germany, almost 14,000 men die every year from PC [4].
Although treatment for patients with mCRPC is limited 
to palliative care, several treatment options are available. 
Depending on clinical symptoms, performance status, 
pretreatment, and patient preferences, treatments include 
immunotherapy, hormonal therapy, chemotherapy, and 
supportive measures (best supportive care [BSC]) [5]. 
Treatment options improved with the introduction of doc-
etaxel, which was the first drug to improve survival in 
patients with mCRPC and has been the standard first-line 
therapy since 2004 [6, 7]. Further life-prolonging drugs 
became available with the approval of cabazitaxel chemo-
therapy in 2010, followed by the hormonal drugs abira-
terone and enzalutamide [5]. Cabazitaxel was designed to 
overcome docetaxel resistance. In the TROPIC phase III 
trial, cabazitaxel led to a significant increase in median 
overall survival compared with mitoxantrone (15.1 vs. 
12.7 months) in patients pretreated with docetaxel [8]. 
Antineoplastic activity of cabazitaxel has also been shown 
in patients with progressing mCRPC pretreated with doc-
etaxel and hormonal drugs (abiraterone or enzalutamide) 
[9]; however, as a first-line treatment, cabazitaxel did not 
demonstrate superiority over docetaxel in terms of overall 
and progression-free survival [10]. Cabazitaxel also raised 
some concerns as it induced a significantly higher risk 
of grade III/IV neutropenia compared with mitoxantrone 
(82 vs. 58%, respectively) [8]. Current German guidelines 
recommend cabazitaxel as second-line therapy for patients 
with mCRPC with disease progression during or after doc-
etaxel treatment and a good performance status [11].
Although treatments have expanded rapidly, informa-
tion on their financial impact is limited. In the EU, the 
total economic burden of PC was estimated to be €8.43 
billion in 2009, of which €5.43 billion was attributable to 
direct healthcare costs. Germany has Europe’s highest PC 
healthcare expenditure per person [12]. PC costs of illness 
(COI) in Germany were estimated at approximately €1.85 
billion in 2015 [13]. Focusing on COI analyses in the field 
of mCRPC, a recently published worldwide review [14] 
reported a broad range of cancer-specific healthcare costs, 
depending on the characteristics of included patients. 
However, only few studies have stratified costs by treat-
ment, with most focusing exclusively on selected treat-
ments—for example, hormonal therapy [15–17]—only 
considering pharmacy costs [15, 18, 19], and/or estimat-
ing costs for a hypothetical patient population (literature-
based cost analysis) [16, 20]. Since mCRPC healthcare 
costs have not previously been reported for Germany [14, 
21] and the evidence for real-world outcomes of mCRPC 
stratified by contemporary treatment are limited, this 
study’s purpose is to analyze the healthcare resource uti-
lization (HRU) for patients with mCRPC and the costs 
of treatment with cabazitaxel, docetaxel, abiraterone, and 
enzalutamide in comparison with BSC. This can provide 
valuable information for decision makers and clinician 
leaders regarding public access to innovative treatments 
and optimal treatment decisions.
2  Methods
2.1  Perspective
This analysis was conducted to evaluate the economic bur-
den of mCRPC in terms of statutory health insurance (SHI). 
Claims data were obtained from one of the largest sickness 
funds in Germany, the Techniker Krankenkasse, covering 
approximately 10 million individuals in 2017 [22]. The anal-
ysis includes HRU and pharmaceutical costs (ready-to-use 
drugs and cytostatic agents), outpatient and inpatient care, 
and sick leave payments. Copayments and out-of-pocket 
payments were not considered because costs were analyzed 
from an SHI perspective.
2.2  Study Population
Patient identification required documentation for at least one 
inpatient diagnosis, secured outpatient diagnosis, or hospital 
outpatient diagnosis for PC based on the International Clas-
sification of Diseases, Tenth Revision, German Modification 
(ICD-10-GM code C61) between 2014 and 2016. All male 
sample patients had to be continuously insured from 2014 to 
2017 or until death (whichever came first). Identification of 
metastases was based on ICD codes C77, C78, and C79. To 
ensure the metastasis diagnosis was associated with PC (ICD 
codes do not include information on the primary tumor), 
patients were only included if ICD code C61 was docu-
mented in the same quarter. To ensure resources and costs 
were not influenced by additional cancer therapies, patients 
were excluded if further malignant neoplasms (ICD code 
‘C’) were documented (in an inpatient or secured outpatient 
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diagnosis), with the exception of the following ICD codes: 
C20 (rectum), C41 (bone and articular cartilage of other 
and unspecified sites), C43/C44 (skin), C67 (bladder), C68 
(other and unspecified urinary organs), C80 (malignancies 
without specification of side), and C85 (other and unspeci-
fied types of non-Hodgkin lymphoma). We allowed for 
malignancies that were judged by our clinical expert to be 
associated with locally advanced PC, for example malignant 
neoplasms of the bladder and rectum. Additionally, we did 
not exclude malignant neoplasms where the therapies did not 
compete with PC treatment (e.g., skin cancer).
Following current clinical practice guidelines for PC at 
the time of cohort selection [23–25], first-line therapy for 
maintaining castrate testosterone levels (androgen-depri-
vation therapy) was defined as at least one prescription of 
luteinizing hormone-releasing hormone (LHRH) agonists/
antagonists identified through drug claims (L02AE01, 
L02AE02, L02AE03, L02AE04, L02BX01, L02BX02, 
and H01CA04). As regards second-line treatment, patients 
were categorized into five treatment groups: cabazitaxel, 
docetaxel, abiraterone, enzalutamide, and BSC. Patient 
allocation to cohorts was based on patients undergoing a 
first-line therapy who received either one of the second-line 
drugs or, for BSC, at least one of the selected outpatient/
inpatient health services (e.g., pain therapy, radiotherapy, 
blood transfusion), as shown in Table 1 in the electronic 
supplementary material (ESM). As patients received multi-
ple treatments (consecutively or in parallel), patient alloca-
tion to cohorts was based on clinical knowledge defining 
further criteria for continuous treatment. For inclusion in 
the cabazitaxel cohort, continuous treatment was defined as 
at least three cycles of chemotherapy within 90 days. For 
the docetaxel cohort, at least six cycles of chemotherapy 
were required, with three cycles given within 90 days. In the 
cabazitaxel and docetaxel cohorts, patients were excluded if 
they were not cabazitaxel naive and docetaxel naive, respec-
tively, namely, if there was an initial drug prescription before 
the first-line index date. Reflecting clinical knowledge on 
the time period in which the first signs of resistance (i.e., 
prostate-specific antigen progression) can occur [26–28], 
in the abiraterone and enzalutamide cohorts, continuous 
treatment was defined as lasting at least 180 days, with at 
least six prescriptions within 180 days (with an average gap 
between pharmacy claims up to a maximum of 34 days). 
For the BSC cohort, we first restricted the potential pool of 
first-line therapy patients with mCRPC to those never having 
received cabazitaxel, docetaxel, abiraterone, or enzalutamide 
after first-line therapy. Inclusion in the BSC cohort required 
at least one BSC-specific healthcare service in addition to a 
PC diagnosis and an observation period of at least 180 days. 
In the hormonal cohorts and BSC, patients who received at 
least one cycle of chemotherapy (cabazitaxel or docetaxel) 
in the 3-month baseline period were excluded.
2.3  Study Design
The date of the first claim of chemotherapy/medication 
prescription or health service received (only in the BSC 
group) was defined as the index date. The study period 
spanned from that date until (1) death, (2) data cutoff (31 
December 2017), (3) drug switch, or (4) discontinuation 
of therapy, whichever came first. In case (4), the observa-
tion period ended with the last claim plus 21 days (end of 
cycle) of cabazitaxel/docetaxel and plus 30/28 days (pre-
scription length) in abiraterone/enzalutamide.
Complete claims data for patients meeting the eligi-
bility criteria were extracted and the following baseline 
characteristics obtained: age at index date, duration of 
observation, and comorbidities. Patients’ comorbidities 
were measured 1 year prior to the index date using the 
well-established pharmacy-based metrics (PBM) [29], 
which have been developed for risk adjustment in health-
care utilization. PBM include 32 binary indicators of 
chronic conditions identified by prescription claims data. 
Since diseases might not always be documented as ICD 
codes, filled prescriptions might reflect patients’ percep-
tion of severe conditions that warrant treatment. To avoid 
overadjustment, PBM group 9 (including drug codes for 
malignancies) was discarded.
As the duration of observation differed between indi-
viduals, we calculated resource use and costs for the entire 
study period but reported them as monthly values. HRU 
was measured as the average number of drug prescrip-
tions, outpatient visits, hospital outpatient visits, hospital 
admissions, hospital days, and days with sickness benefits. 
The number of outpatient visits was determined by adding 
up the number of invoiced services based on the uniform 
value scale per day and medical specialist [30].
Healthcare costs (€) were also extracted, but no adjust-
ments were made to a common year of valuation. To iden-
tify cost drivers, costs were analyzed by type. For each 
inpatient stay and sick leave period, costs were divided 
by the length of stay/duration and calculated according to 
the start and end of observation. For inpatient stays where 
the discharge day occurred after the end of observation, 
only costs within the follow-up period were considered. To 
obtain outpatient care costs, we calculated average costs 
per quarter day [30] and multiplied them by the number 
of days under observation in that quarter. Moreover, over-
all healthcare costs were calculated as the sum of costs 
from all domains. Whenever possible, HRU and costs were 
reported separately for all mCRPC-related events (defined 
as mCRPC-related medication or claims with a PC diag-
nosis) and regardless of underlying medical reasons (all-
cause HRU and costs).
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2.4  Statistical Analyses
To compare baseline characteristics, we reported absolute 
and relative frequencies for categorical variables and sum-
marized continuous variables using the mean, standard devi-
ation, and median. Differences between cohorts regarding 
patient characteristics and outcomes were analyzed using 
Chi-squared tests or Fisher’s exact tests (count <5) for cat-
egorical variables and Mann–Whitney U tests (two groups) 
and Kruskal–Wallis tests (more than two groups) for con-
tinuous variables. Significance was determined at the level 
of ≤ 0.05.
We conducted unadjusted and adjusted comparisons. The 
HRU and cost outcomes of patients treated with cabazitaxel, 
docetaxel, abiraterone, and enzalutamide were compared 
with those of the patients in the BSC cohort. Adjustments 
were made for the following covariates: age groups, further 
malignancies documented in patients with mCRPC, and 
comorbidities according to PBM. For adjusted comparisons 
of HRU, incidence rate ratios (IRRs) were estimated using 
Poisson-specified regression models with or without zero 
inflation (depending on the model fit). To address uncer-
tainties, we applied bootstrap analysis with 1000 samples 
per model for calculating the confidence intervals (CIs). For 
cost prediction, we estimated two-part models for all cost 
categories where the dependent variable was zero for at least 
one observation. Thus, we split the analysis into two parts, 
i.e., first fitting the probability of observing a positive versus 
zero outcome and then analyzing positive costs using linear 
regression based on ordinary least squares or generalized 
linear models with a gamma distribution, and identity link 
function, depending on the model fit. While the cohort esti-
mates are provided exclusively in the following tables and 
figures, the entire output for all-cause healthcare costs is 
provided in Table 4 in the ESM (as a check for robustness).
To compare our results with those from other studies, 
we converted costs to € using the average exchange rate of 
a given year as listed in Eurostat [31] and reported them 
as monthly costs. Data management and statistical analyses 
were performed with SAS 9.4 for Windows, SAS Institute 
Inc., Cary, NC, USA.
3  Results
3.1  Study Population
We identified 92,712 patients (see Fig. 1) with a PC diag-
nosis in 2014–2016 who were continuously enrolled until 
the end of 2017 or to death, whichever came first. Of the 
8525 patients with metastases, 5771 received first-line 
treatment with LHRH agonists or antagonists. Using 
the study inclusion criteria concerning the number of 
prescriptions, continuous treatment, and pretreatment, 
patients were treated as follows: cabazitaxel (n = 240), 
docetaxel (n = 539), abiraterone (n = 486), enzalutamide 
(n = 351), and BSC (n = 2328).
Table 1 presents patient demographics and baseline 
characteristics. With an average age of 71 years, patients 
receiving cabazitaxel and docetaxel were significantly 
(p < 0.0001) younger (by approximately 3 years) than 
patients starting hormonal therapy or BSC. In the cabazi-
taxel and docetaxel cohorts, there was a larger propor-
tion of individuals aged < 70 years and a smaller share 
of individuals in the oldest age group (≥ 80 years). The 
median duration of observation ranged between 4 months 
in the cabazitaxel cohort and 24 months in the BSC cohort. 
When considering comorbidities at baseline, patients in 
the cabazitaxel cohort had the highest mean number of 
PBM groups, and BSC patients had the lowest. As shown 
in supplementary Table 2, 16 of 31 PBM groups differed 
significantly between cohorts. Cardiovascular diseases, 
rheumatic conditions, acid peptic diseases, and pain/
inflammation were the most frequent chronic conditions 
documented in the 12 months preceding the index date.
3.2  Healthcare Resource Use
In most types of all-cause healthcare consumption, average 
unadjusted and adjusted utilization rates were highest for the 
cabazitaxel and lowest in the BSC group (Fig. 2). Adjusted 
analyses show that patients in the cabazitaxel, docetaxel, abi-
raterone, and enzalutamide cohorts had significantly more 
all-cause drug prescriptions, outpatient visits, and hospital 
outpatient visits than those in the BSC cohort (reference 
category). Cabazitaxel treatment was associated with a sig-
nificantly higher number of all-cause inpatient admissions 
per month (IRR 2.34; 95% CI 1.77–2.93), even in compari-
son with all other cohorts. Moreover, patients in the chemo-
therapy cohorts spent significantly more days in hospital 
per month (cabazitaxel: IRR 2.57 [95% CI 1.65–3.77]; doc-
etaxel: IRR 1.71 [95% CI 1.09–2.32]), whereas IRRs in the 
antihormone cohorts did not differ significantly from those 
receiving BSC. No significant differences existed in adjusted 
HRU between abiraterone and enzalutamide groups.
With the exception of inpatient admissions, a similar 
trend was observed in mCRPC-related HRU (Fig. 1 in the 
ESM). After adjusting for baseline covariates, all treatment 
cohorts showed a significantly higher number of mCRPC-
related inpatient admissions compared with the BSC cohort. 
The adjusted IRRs (95% CIs) were 3.02 (2.14–4.02) for 
cabazitaxel, 1.48 (1.14–1.92) for docetaxel, 1.40 (1.11–1.76) 
for abiraterone, and 1.34 (1.06–1.68) for enzalutamide.
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3.3  Healthcare Costs
Adjusted monthly all-cause healthcare costs per patient 
(Fig. 3) totaled €7631 for cabazitaxel and were approxi-
mately three times higher than for docetaxel (€2392), 1.5 
times higher than for abiraterone (€5226) and enzaluta-
mide (€5079), and eight times higher than for BSC (€959). 
mCRPC-related healthcare costs accounted for 46–88% of 
monthly all-cause costs.
Except for hospital outpatient care, unadjusted cost analy-
ses showed significant differences in healthcare costs among 
all cohorts (Table 3 in the ESM) and in most cost domains 
when considering cost differences compared with BSC 
(Table 2). Controlling for baseline covariates in mCRPC-
related cost regression, Table 2 revealed that the probability 
of getting treatment did not differ significantly in all domains 
compared with BSC. However, if treatment occurred, costs 
associated with cabazitaxel or docetaxel treatment were 
significantly higher in almost all cost domains. Regard-
ing cost distribution, variations were most prominent for 
pharmaceutical treatment, followed by inpatient care and 
sick leave payments. Compared with BSC, the adjusted 
differences (95% CI) in mCRPC-related monthly prescrip-
tions and inpatient treatment were €4318 (4066–4428) and 
€417 (267–578), respectively, for cabazitaxel and €984 
(914–1016) and €101 (38–170), respectively, for docetaxel. 
Thus, cabazitaxel-treated patients had significantly higher 
monthly drug and inpatient care costs when directly com-
pared with those for patients receiving docetaxel. With 
respect to antihormonal therapy, the monthly burden of 
hospitalization in the abiraterone cohort was similar to that 
in the BSC cohort, and enzalutamide-treated patients did 
not differ with respect to hospital outpatient care and sick 
leave payments.
With regard to all-cause healthcare costs, adjusted dif-
ferences showed a similar trend with drug prescription 
accounting for by far the majority of all-cause costs. No 
significant cost differences existed between abiraterone- and 
enzalutamide-treated patients in adjusted regression models.
In general, older age was associated with signifi-
cantly lower all-cause monthly healthcare costs (Table 4 
in the ESM). Compared with patients aged <65 years, 
Fig. 1  Cohort selection. BSC best supportive care, ICD International Classification of Diseases, LHRH luteinizing hormone-releasing hormone, 
mCRPC metastatic castration-resistant prostate cancer, mPC metastatic prostate cancer, PC prostate cancer
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the gamma-specified regression model on all-cause costs 
showed a cost reduction of €316 for patients aged 65–69 
years, €420 for patients aged 70–74 years, €329 for patients 
aged 75–79 years, and €286 for patients aged ≥80 years. 
The presence of the following chronic conditions signifi-
cantly increased monthly all-cause costs (descending order): 
end-stage renal disease (€3633), HIV (€1003), pain (€458), 
anti-arrhythmics (€281), rheumatic conditions (€181), Par-
kinson’s disease (€155), diabetes (€147), acid peptic disease 
(€101), and pain and inflammation (€88).
4  Discussion
This study provides insights into the HRU and costs of 
mCRPC for cabazitaxel, docetaxel, abiraterone, enzaluta-
mide, and BSC in a real-world setting. It also contributes to 
an understanding of which factors drive costs. It highlights 
the high healthcare burden related to patients with mCRPC, 
especially those treated with cabazitaxel. Our analysis 
used claims data from one of the largest sickness funds in 
Germany, providing a greater sample size than most other 
COI studies on mCRPC [14, 32]. The participants’ mean 
age (73 years) is similar to the previously reported mean 
age at CRPC diagnosis [1, 14]. Cabazitaxel- and docetaxel-
treated patients were about 3 years younger than those in 
the other groups. At baseline, there were significant differ-
ences in the burden of disease across cohorts, with patients 
receiving cabazitaxel showing the highest mean number of 
comorbidities.
This study also revealed that HRU and costs highly 
depend on the treatment. Existing literature shows a wide 
range of healthcare costs in mCRPC [14, 32], but only few 
studies stratify costs by treatment. We found that, with few 
exceptions, adjusted IRRs were highest with cabazitaxel 
and lowest with BSC. Accordingly, cabazitaxel resulted in 
the highest healthcare costs by far, followed by abiraterone, 
enzalutamide, docetaxel, and BSC. Although we did not 
find any study analyzing healthcare costs by all the treat-
ments used here, these cost proportions were also observed 
in studies comparing treatment with selected chemotherapies 
and hormonal therapies [18, 20, 33]. The higher economic 
burden with cabazitaxel was mainly due to higher drug costs 
and a greater need for inpatient treatment, even compared 
with docetaxel. As we detected large differences in CIs con-
cerning hospitalization, further research should investigate 
Table 1  Patient demographics 
and baseline characteristics
Cohorts differ significantly (p < 0.0001) in all baseline characteristics. Differences were analyzed using 
Chi-squared tests for categorical variables and Kruskal–Wallis tests for continuous variables
BSC best supportive care, SD standard deviation
a Follow-up duration was measured as the time span from the index date until the end of observation (death, 
drug switch, discontinuation of therapy, or data cutoff, whichever came first)
b Comorbidities were assessed using a pharmacy-based metric with 32 classes. The redundant group of 
malignancies (group 9) was excluded
Cabazitaxel Docetaxel Abiraterone Enzalutamide BSC
Age
Years, mean ± SD 70.61 ± 7.7 70.46 ± 7.8 73.98 ± 7.7 74.72 ± 8.2 73.74 ± 8.6
Years, median 72 72 75 76 75
Age group, n (%)
<65 years 48 (20.0) 122 (22.6) 63 (13.0) 43 (12.3) 317 (13.6)
65–69 years 40 (16.7) 108 (20.0) 53 (10.9) 43 (12.3) 314 (13.5)
70–74 years 62 (25.8) 126 (23.4) 121 (24.9) 72 (20.5) 528 (22.7)
75–79 years 70 (29.2) 121 (22.5) 132 (27.2) 94 (26.8) 616 (26.5)
≥80 years 20 (8.3) 62 (11.5) 117 (24.1) 99 (28.2) 553 (23.8)
Follow-up durationa
Months, mean ± SD 4.5 ± 2.5 5.6 ± 2.9 16.2 ± 9.7 15.7 ± 7.9 26.3 ± 12.7
Months, median 4.2 4.5 12.7 13.4 24.2
Comorbiditiesb
Mean ± SD 5.2 ± 2.3 4.6 ± 2.5 4.0 ± 2.4 4.4 ± 2.7 3.6 ± 2.5
Comorbidity classesb, n (%)
0 2 (0.8) 9 (1.7) 25 (5.1) 21 (6.0) 203 (8.7)
1–3 53 (22.1) 192 (35.6) 208 (42.8) 123 (35.0) 1028 (44.2)
4–6 123 (51.3) 219 (40.6) 182 (37.5) 128 (36.5) 806 (34.6)
7–9 51 (21.3) 103 (19.1) 64 (13.2) 67 (19.1) 247 (10.6)
≥10 11 (4.6) 16 (3.0) 7 (1.4) 12 (3.4) 44 (1.9)
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whether the increased number of hospital admissions might 
be due to planned hospitalizations to administer chemo-
therapy or the result of serious adverse events (e.g., febrile 
neutropenia) related to cabazitaxel. Controlling for baseline 
covariates, higher all-cause drug costs with cabazitaxel 
might stem from the fact that these patients are generally 
treated with more comedication to increase the safety and 
tolerability of chemotherapy than were the other mCRPC 
cohorts. Moreover, the higher sick leave payments in the 
chemotherapy cohorts might reflect the greater proportion of 
patients entitled to sickness allowance (employed individu-
als) combined with higher hospitalization rates.
Compared with existing literature on absolute cost values, 
our analysis revealed that, with €6343 for cabazitaxel and 
Unadjusted 
incidence rate 
per person-month
2.65 [2.46-2.87] 7.97
2.55 [2.40-2.74] 6.87
1.75 [1.67-1.85] 4.45
1.56 [1.48-1.65] 4.28
1.00 2.39
2.10 [1.95-2.27] 8.91
2.10 [1.98-2.21] 8.25
1.19 [1.13-1.24] 4.55
1.15 [1.10-1.21] 4.49
1.00 3.73
2.20 [1.50-3.14] 0.09
2.09 [1.63-2.68] 0.08
1.98 [1.56-2.46] 0.07
1.51 [1.12-1.93] 0.05
1.00 0.03
2.34 [1.77-2.93] 0.31
1.15 [0.93-1.37] 0.13
1.16 [0.98-1.37] 0.12
1.11 [0.93-1.32] 0.12
1.00 0.09
2.57 [1.65-3.77] 1.54
1.71 [1.09-2.32] 0.84
1.00 [0.81-1.29] 0.89
0.90 [0.70-1.17] 0.73
1.00 0.75
1.76 [0.97-2.81] 1.43
2.58 [1.85-3.50] 2.30
1.90 [1.12-2.98] 0.32
0.82 [0.32-1.42] 0.19
1.00 0.45
Days with sick leave 
paymentsc
Associated with higher
resource ulizaon
Associated with lower 
resource ulizaon 
Adjusted IRRa
Adjusted IRRa 
[95% CI]
Drug prescripons
Outpaent visitsb
Hospital outpaent 
visits
Hospital admissions
Days of 
hospitalizaon
0 1 2 3 4
Cabazitaxel Docetaxel Abiraterone Enzalutamide Best supporve care
Fig. 2  Monthly all-cause health resource utilization by cohort. CI 
confidence interval, IRR incidence rate ratio. aIRRs were estimated 
using Poisson-specified regression models with or without zero infla-
tion (depending on the model fit). Adjustments were made for the 
following baseline covariates: age groups, comorbidities (pharmacy-
based classes), and further malignancies documented in patients with 
mCRPC. For calculation of CIs, a total of 1000 bootstrap samples 
were used. An estimate is statistically significant whenever the confi-
dence interval does not include 1.0 (does not cross the vertical axis). 
bThe unadjusted number of outpatient visits is underestimated. Flat-
rate fees mean that not every outpatient consultation is documented 
in German claims data. cIf an illness lasts longer than 6 weeks, the 
employee will receive sick leave payments from the health insurance 
covering 70% of the gross salary for up to 78 weeks
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€1580 for docetaxel, the monthly total mCRPC-related costs 
for chemotherapy seem to be slightly lower. In US/Cana-
dian budget impact analyses/modelling approaches, monthly 
cabazitaxel treatment has been priced at €6182 (2013) for 
primary medication [18] and €9823–10,546 (2012) for drugs 
and administration [20]. The corresponding values for doc-
etaxel were €566 (2013) for drugs [18]; €1310 (2014) for 
drugs, administration, concomitant medication, monitoring, 
and adverse events [33]; and €2817–3275 (2012) for doc-
etaxel retreatment drug and administration [20]. However, 
variations might be explained by differences in healthcare 
system structure, reimbursement schemes, unit costs, and 
practice patterns [34].
Regarding antihormonal therapy, our analysis revealed 
monthly mCRPC-related healthcare costs of €4579 for 
abiraterone and €4416 for enzalutamide. Although abira-
terone treatment monthly pharmacy costs are similar to 
those previously reported in US studies, averaging approxi-
mately €4500 (2012/2014/2017) [15, 17, 20], monthly total 
mCRPC-related costs are reported to be higher in most US 
studies, ranging from €5727 (2014) to €9715 (2017) [16, 
17, 33]. However, some of these studies included additional 
cost domains (e.g., post-progression treatments and end-of-
life care). Comparing enzalutamide to abiraterone, some 
US studies [15, 17, 33] considered its pharmacy costs to be 
higher but costs beyond drug acquisition (e.g., monitoring, 
adverse events, and end-of-life care [16, 17]) to be lower. 
By contrast, a recent claims data analysis [17] failed to show 
significant differences in total mCRPC-related healthcare 
costs. Controlling for baseline covariates, we did not find 
any significant differences in HRU and healthcare costs 
between these groups.
With monthly costs of €438, by far the lowest HRU and 
costs in most domains were observed with BSC. As its aim 
is to minimize symptom burden and maintain quality of life 
without directly affecting tumor activity, drug costs remain 
relatively low. As BSC covers a wide range of services, 
relevant drugs (e.g., cortisone) might have been neglected, 
thus underestimating costs. Since some health services (e.g., 
drugs) are not documented with an ICD diagnosis in German 
claims data, non-indication-specific medication is difficult 
to allocate to the underlying disease. However, consulting a 
clinical expert, we defined key treatment options in patients 
receiving BSC, including disease surveillance, pain therapy, 
radiotherapy, and blood transfusion. Further research is nec-
essary to describe the BSC population and capture all kinds 
of supportive services.
Irrespective of the treatment, like previous studies [14, 
17, 21, 35–37], our analysis highlights the financial impact 
of medication, followed by that of inpatient care (and partly 
sick leave payments) as the most important cost drivers in 
mCRPC. Moreover, across all cohorts, the youngest patients 
were the costliest per month. Although the age gradient has 
been a controversy discussed in PC treatment [36, 38, 39], 
it might be explained as follows: depending on their per-
formance status, older men might receive a smaller dose 
of chemotherapy and thus have a lower risk of developing 
serious adverse events requiring intensive treatment.
Some limitations must be mentioned, most of which are 
inherent in the database (for an overview, see Kreis et al. 
[40] and Neubauer et al. [41]). First, patient allocation to 
treatment cohorts was based exclusively on services reim-
bursed by SHI. As claims data are routinely collected for 
billing and reimbursement, information on clinical param-
eters, such as cancer stage or tumor type, were not avail-
able for patient selection or cost stratification. Moreover, as 
already stated [32], we did not find a completely validated 
algorithm identifying patients with mCRPC in the literature. 
Fig. 3  Adjusteda mean monthly 
healthcare costs in patients 
with mCRPC by therapy. BSC 
best supportive care, mCRPC 
metastatic castration-resistant 
prostate cancer. aAdjusted mod-
els controlled for the following 
baseline covariates: age groups, 
comorbidities (pharmacy-based 
classes), and further malignan-
cies documented in patients 
with mCRPC
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However, consulting a clinical expert, we developed an algo-
rithm identifying patients with PC, metastasis, castration 
resistance, and second-line treatment, using a wide range 
of different classification systems for claims data. There is a 
strong likelihood that mCRPC in the final treatment cohorts 
was appropriately captured because inclusion required the 
prescription of (predominant) disease-specific drugs and 
evidence of continuous treatment.
Second, regarding HRU, the number of outpatient visits 
is underestimated. Flat-rate fees mean that not every out-
patient consultation is documented in German claims data; 
for example, a patient may go to the doctor several times per 
quarter but be documented as a single treatment case [30]. 
Moreover, as only quarterly outpatient care cost data were 
available, costs might not have been assigned adequately 
depending on the varying treatment duration of drug groups. 
However, in a sensitivity analysis, we calculated costs by 
using the date of treatment in the database, confirming our 
main results. Third, similarly, mCRPC-related medication 
costs and consequently total mCRPC-related healthcare 
costs by treatment group are rather underestimated because 
the costs of comedication (e.g., antiemetics) and adverse 
events (e.g., nausea, stomatitis, and diarrhea) associated 
with the primary therapy were not considered in the analy-
sis. Since drug claims are not linked with a diagnosis in 
German claims data, the assignment of costs from non-
indication-specific drugs is challenging. However, we used 
a conservative approach to estimate mCRPC-related costs 
and calculated all-cause drug costs to report the maximum 
of healthcare costs.
Novel agents in the field of hormonal manipulation and 
chemotherapies are rapidly changing the available mCRPC 
treatments; therefore, patient allocation to cohorts repre-
sented a challenge, requiring further criteria for continu-
ous treatment. To achieve the aims of palliative treatment, 
proper sequencing and effective combination of available 
agents becomes increasingly important for both clinicians 
and researchers. Although general guidelines on treatment 
options and algorithms exist [11, 23, 24], studies on the opti-
mal choice, combination, and sequence of agents to maxi-
mize the clinical benefits (and minimize cross-resistance) 
[5, 42] or define thresholds for therapy changes are lacking.
5  Conclusion
This is the first study to assess all-cause and PC-related HRU 
and costs in patients with mCRPC stratified by five contem-
porary treatments reflective of real clinical practices. In Ger-
many, mCRPC treatment represents a high economic burden 
for SHI. Our study observed substantial differences in age, 
HRU, and costs with cabazitaxel, docetaxel, abiraterone, 
enzalutamide, and BSC. Cabazitaxel- and docetaxel-treated 
patients were significantly younger than those receiving the 
other treatments. In most domains, cabazitaxel was associ-
ated with the highest HRU and healthcare costs because of 
the higher drug costs and inpatient care required. Future 
analyses should examine the reasons for this greater need 
for inpatient treatment and assess the financial impact 
with respect to survival time and adverse event rates. With 
expanding treatment options for patients with mCRPC 
resulting in an increased economic burden, public access to 
innovative agents and optimal therapeutic strategies should 
be carefully evaluated.
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